Myeloma CAR T-Cell Therapy in 2026: Why Timing Matters Most

Introduction: A Narrowing Window of Opportunity

Chimeric antigen receptor (CAR) T-cell therapy is one of the most effective tools available against relapsed or refractory multiple myeloma. Yet a growing body of evidence shows that its real-world benefit depends heavily on when the referral process begins, not simply whether a patient qualifies. A patient who is eligible on paper can lose that opportunity if the disease progresses, organ function declines, or a manufacturing slot never opens up.

The stakes have never been higher. Multiple myeloma remains incurable, but it is increasingly manageable. In the United States, the five-year survival rate has nearly doubled since the mid-1990s, rising from 32% to 62%. As treatment options multiply, decisions about sequencing and timing carry more weight than ever, because the order in which therapies are used can shape what remains available later.

This article translates the clinician-level debates of 2026 into a plain-language framework that patients and caregivers can use to advocate for timely referral. Those debates include the comparison of the CARTITUDE-4 and MajesTEC-3 trials, data on “waitlist mortality,” and ongoing capacity constraints. The focus here is not a detailed explanation of how Abecma and Carvykti work, nor a full walkthrough of the treatment journey. Instead, it centers on one critical question: when should the CAR-T conversation start?

Why 2026 Changed the Calculus: Earlier-Line Approvals

For years, CAR-T therapy in myeloma was considered a late-stage option. That changed in April 2024, when the U.S. Food and Drug Administration (FDA) approved both idecabtagene vicleucel (ide-cel, sold as Abecma) and ciltacabtagene autoleucel (cilta-cel, sold as Carvykti) for use earlier in the treatment course.

The new eligibility thresholds are specific:

• Cilta-cel (Carvykti) is approved after just one prior line of therapy, provided that line included a proteasome inhibitor and an immunomodulatory drug such as lenalidomide.
• Ide-cel (Abecma) is approved after at least two prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

This marks a significant departure from the earlier paradigm. Under the original approvals (Abecma in March 2021 and Carvykti in February 2022), CAR-T was generally reserved for patients whose disease had failed three or more prior therapies. In practice, that meant many patients arrived at CAR-T already weakened by multiple regimens and aggressive disease.

The practical implication for 2026 is clear: patients and families may need to start thinking about CAR-T far sooner than they assume. For some, the right time to raise the topic is at first relapse, rather than after exhausting multiple regimens.

The New Crossroads: CAR-T or Bispecific Antibodies at First Relapse?

The central clinical debate of 2026 revolves around a genuine choice point. Following the publication of CARTITUDE-4 and MajesTEC-3, both cilta-cel and teclistamab combined with daratumumab (a bispecific antibody combination) are now FDA-approved for myeloma at first relapse. Oncologists, patients, and caregivers must now weigh which approach to use first.

The two approaches differ in important ways:

• CAR-T therapy is a one-time infusion of a patient’s own genetically modified T cells. It requires collection, manufacturing, and a period of close monitoring, but it can offer deep, durable responses without continuous treatment.
• Bispecific antibodies are “off-the-shelf” drugs that can be started relatively quickly. They are typically given on an ongoing basis, which means continued clinic visits and cumulative exposure to side effects such as infections.

A growing number of experts favor using CAR-T earlier, in part to preserve bispecific antibodies as a later salvage option. The reasoning is straightforward: CAR-T relies on the health and fitness of a patient’s own T cells, which can be depleted by repeated lines of therapy. Bispecific antibodies, by contrast, may remain usable after CAR-T.

This is not a universal rule. Some patients may be better suited to a bispecific first because of disease pace, logistical constraints, or personal priorities. But the existence of this debate means one thing for families: the sequencing decision should be discussed deliberately, not made by default.

The Hidden Cost of Waiting: Referral Bottlenecks and Capacity Limits

Even when a product is approved and a patient is eligible, access is not guaranteed. This access gap is the most practical reason timing matters so much.

Estimates suggest that 60% to 80% of patients may be eligible for CAR-T at first relapse, yet only 10% to 30% actually receive it. That gap is driven largely by referral delays and capacity constraints, not just clinical ineligibility. Many patients are never referred to a CAR-T center, are referred late, or face waits that allow their disease to advance.

Manufacturing capacity has historically been a significant bottleneck. One hematologist at the University of California, San Francisco described having only four manufacturing slots available for the two myeloma products, while roughly 50 to 60 eligible patients were waiting.

The consequences of that scarcity are measurable. A University of Kansas study on “waitlist mortality” followed 40 patients waiting for CAR-T. Of these, 24 (60%) secured a production slot, while 16 (40%) did not. Median overall survival was not reached in the group that received CAR-T, compared with just 9 months in the group that did not.

While capacity has improved in some regions, these findings highlight a sobering reality: delays are not neutral. Time spent waiting can translate directly into lost options.

Recognizing the Right Moment to Start the Referral Conversation

Data is only useful if it leads to action. Patients and caregivers can play an active role by recognizing the moments when CAR-T should be raised, rather than waiting until a crisis forces the issue.

Key Moments to Raise CAR-T

• At diagnosis or early in treatment: It is reasonable to ask whether CAR-T may be part of the long-term plan, even if it is not yet needed.
• When lab markers begin to rise: A climbing M-protein or free light chain level may signal early relapse, often before symptoms appear.
• At first confirmed relapse: Under current approvals, this may already be the point of eligibility for cilta-cel.
• When a current regimen is no longer tolerated: Side effects that force a change in therapy are another natural decision point.
• Before starting a new line of therapy: Each new regimen can affect future CAR-T eligibility and T-cell fitness.

Questions to Bring to the Oncologist

1. Based on my treatment history, am I eligible for CAR-T now, or when would I become eligible?
2. Should CAR-T or a bispecific antibody come first in my case, and why?
3. Would my next treatment affect my ability to receive CAR-T later?
4. Can I be referred to a CAR-T center now for an evaluation, even if I am not ready to proceed?
5. How long are current wait times for apheresis and manufacturing slots at nearby centers?
6. What bridging therapy would I receive while my cells are being manufactured?
7. Which CAR-T product would be recommended for me, and what are the trade-offs?
8. What support will my caregiver and I need during the monitoring period?

Writing these questions down and bringing them to appointments helps ensure the conversation happens, even during busy or emotionally difficult visits.

What Happens Once the Referral Process Begins

Understanding the general timeline reinforces why early referral matters. The CAR-T process spans roughly three months from T-cell collection to first response evaluation.

• Leukapheresis begins the process by collecting the patient’s T cells.
• Manufacturing typically takes four to six weeks. During this time, most patients receive bridging therapy to keep the disease under control. Most centers report bridging more than 85% of their patients, most often with proteasome inhibitors or immunomodulatory drugs, and bridging typically lasts one to two months.
• Lymphodepleting chemotherapy and infusion follow once the cells are ready.
• Close monitoring comes next. Patients typically need to remain near the treatment center for about four weeks after infusion for observation and recovery, which requires a dedicated caregiver.

This multi-month runway is precisely why starting the referral and apheresis process early is so important. If referral begins only after disease is advancing rapidly, there may not be enough time to manufacture cells and safely reach infusion. Starting the process before disease progression limits options gives patients and care teams the room they need to plan.

Weighing Abecma and Carvykti in the Context of Earlier Treatment

This section does not re-explain how the two products work. Instead, it considers how differences in efficacy and toxicity factor into earlier-line timing decisions.

Efficacy Differences

A large real-world retrospective comparison of 386 Abecma patients and 255 Carvykti patients, published in the Journal of Clinical Oncology, found that Carvykti was associated with higher overall response and complete response rates. That advantage held across subgroups, including patients with extramedullary disease, high-risk cytogenetics, prior BCMA exposure, and older age. Higher response rates also translated into longer survival outcomes.

This perception of stronger efficacy has shifted clinical practice. Carvykti now holds roughly 80% of the market share among centers offering both products.

Toxicity Trade-Offs

Efficacy is only part of the picture. In the same comparison, Carvykti was associated with higher rates of:

• Severe cytokine release syndrome (CRS)
• Delayed neurotoxicity
• Infections
• A trend toward more secondary malignancies

Common and Rare Side Effects to Plan For

• CRS is common but usually manageable. A meta-analysis of BCMA CAR-T products in 640 myeloma patients found that about 80% experienced some degree of CRS, with roughly 14% experiencing severe (grade 3 or higher) CRS.
• Immune effector cell-associated neurotoxicity syndrome (ICANS) typically emerges five to ten days after infusion, although it can occur later.
• Immune effector cell colitis is a rarer, myeloma-specific complication reported in about 1.2% of patients after Carvykti. It can cause abdominal pain, severe or prolonged diarrhea, weight loss, and elevated liver enzymes, and it usually appears one to three months after therapy, sometimes later. This makes longer-term follow-up planning essential.

Product choice and timing are interconnected. A patient’s age, overall fitness, disease characteristics, and prior treatments all influence which product is preferred and when it should be given. These decisions should be made jointly with a myeloma specialist familiar with the patient’s individual risk profile.

The Pipeline That Could Reshape Future Timing Decisions

Even patients making near-term decisions benefit from understanding what is on the horizon, because emerging therapies may expand future options and influence today’s sequencing choices.

• Anitocabtagene autoleucel (anito-cel) is a next-generation BCMA-targeted CAR-T that uses a novel compact binder. Now owned by Gilead following its acquisition of Arcellx, anito-cel has a Biologics License Application accepted by the FDA as a fourth-line treatment, supported by Phase 1 and pivotal Phase 2 iMMagine-1 data. The FDA decision date is December 23, 2026.
• Arlocabtagene autoleucel (arlo-cel) targets a different antigen called GPRC5D. Published research in Blood suggests it may offer durable responses as a one-time infusion for heavily pretreated patients, including those who progress after BCMA-directed therapy. It may also help avoid some of the on-target, off-tumor toxicity seen with continuous bispecific treatment.
• Allogeneic “off-the-shelf” CAR-T products, made from donor cells rather than a patient’s own, are an active area of research that could eventually shorten wait times.

A therapy targeting a different antigen could serve as a future salvage option after BCMA-directed CAR-T. That possibility may make earlier use of currently available CAR-T even more appealing, since a new path may remain open afterward.

The Bigger Picture: Why Timing Decisions Carry Long-Term Weight

The near-doubling of five-year survival, from 32% to 62%, reflects the cumulative impact of therapies such as CAR-T and other immunotherapies. Yet those gains depend on patients actually reaching these treatments at the right moment.

In 2026, approximately 36,000 new myeloma cases and 10,850 deaths are projected in the United States. Against that backdrop, the gap between the share of patients eligible for CAR-T and the share who receive it represents a solvable problem. Earlier referral is one of the most direct ways to close it.

Timing is not purely a passive outcome determined by the course of the disease. It is, in part, an active decision that patients, caregivers, and care teams can influence through informed questions, prompt referrals, and advance planning.

Conclusion: Start the Conversation Before Disease Progression Limits Your Options

Several developments point to the same conclusion. The earlier-line approvals of 2024, the CAR-T versus bispecific sequencing debate highlighted by CARTITUDE-4 and MajesTEC-3, and documented waitlist mortality data all indicate that earlier referral conversations lead to better outcomes.

Eligibility windows can close quickly as disease progresses. Declining organ function, rapid relapse, or depleted T cells can make CAR-T harder or impossible to pursue. For that reason, proactive discussion with an oncologist is essential rather than optional.

Patients and caregivers are best served by treating the referral and apheresis process as something to plan for early, in partnership with their care team, rather than as a last-resort decision.

Next Steps: Take the Conversation to Your Care Team

• Request a CAR-T eligibility and timing discussion at the next oncology appointment, even if progression has not yet occurred.
• Bring a written list of the questions outlined earlier in this article to ensure nothing is overlooked.
• Seek a second opinion or referral to a specialized myeloma or CAR-T treatment center if the current care team has not raised timing proactively. Organizations such as the International Myeloma Foundation offer caregiver resources and support lines that can help families navigate this step.
• Plan for caregiver support and logistics early, including the roughly four weeks near the treatment center after infusion.

Multiple myeloma remains a demanding diagnosis, but patients today have more effective options than ever before. Informed, timely action is one of the most meaningful ways patients and caregivers can influence outcomes in 2026 and beyond. Starting the conversation early is not about rushing into treatment. It is about keeping every door open for as long as possible.